Developer docs
API playgroundTry for free, no card

Search company profiles

MagIA Diagnostics

Full company profile

uuid00034qp

Namestring
MagIA Diagnostics
Legal namestring
MagIA diagnostics SAS
Company typeenum
Private
Founded yearint
2017
Descriptiontext

MagIA diagnostics SAS is a French in-vitro diagnostics (IVD) company founded in 2017 and headquartered in Échirolles (Grenoble). The company develops a portable point-of-care immunoassay platform built on proprietary superparamagnetic nanoparticle chemistry combined with structured micro-magnet architecture, originating from doctoral research at G2Elab and Institut Néel. Its flagship MforScreen reader weighs under 3.5 kg, runs for over 10 hours on battery, and accepts one or two single-use cartridges simultaneously. The paired MagIA Test Kit (H3S) performs multiplexed screening for HIV, Hepatitis B, Hepatitis C, and Syphilis in 12-15 minutes from 50 µl of capillary or venous blood. A laboratory-format variant, MforLab, extends the same chemistry to a 96-well plate format for bioproduction monitoring under the MAGI@Line project.

The business is currently pre-commercial: products are not yet CE marked, with submission targeted for 2025 following Phase 3 MAGICIENS clinical validation on approximately 6,700 samples. Revenue mechanics are anchored on future hardware (reader) sales paired with consumable cartridge revenue, complemented by European grant funding and collaborative research project income (MAGFA, MAGESTICS, Grand Défi Bioproduction). The go-to-market is a B2B enterprise field-sales motion targeting French and European hospitals, mobile screening units, sub-Saharan African public health programs (via Institut Pasteur and African NGO partners), and biopharmaceutical manufacturers for bioprocess analytics. Go-to-market is reinforced by presence at MEDICA, SFLS, EuroTestWeek, and the Lyonbiopôle/Novéka! cluster. The company has 23 employees, ISO 13485:2016 certification (September 2023), and cumulative funding of approximately €8.2 million across grants, seed, crowdfunding, and a 2024 IVD strategic round, with an additional €5 million earmarked via the European MAGFA project.

Short descriptiontext

MagIA Diagnostics designs portable point-of-care immunoassay readers and multiplexed cartridges that screen for HIV, Hepatitis B/C, and Syphilis from a finger-prick blood sample in 12-15 minutes, serving hospitals, mobile screening units, public health programs in sub-Saharan Africa, and bioproduction customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGrenoble, France
HQ citystring
Grenoble
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, infectious disease screening, multiplex immunoassay, bioproduction monitoring, rapid diagnostic tests
Industry1 code
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
In Vitro Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Point-of-Care Diagnostic Kits and Readers
TypeHardware Sales
Description

Sale of portable diagnostic devices (readers) and associated test cartridges for infectious disease screening. Revenue generated from hardware sales combined with consumable test kits.

magia-diagnostics.com
2Laboratory Diagnostic Solutions
TypeHardware Sales
Description

MforLAB platform for bioproduction monitoring and laboratory-scale analysis, including 96-well format devices and monitoring services.

magia-diagnostics.com
3European Research Project Funding
TypeLicensing Royalties
Description

MAGFA project with €5 million European funding; MAGESTICS project partnership with Infynity Biomarkers SAS and CHU Grenoble Alpes; Grand Défi Bioproduction funding for technology adaptation.

magia-diagnostics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1MforScreen
Description

Point-of-Care portable diagnostic reader system weighing less than 3.5 kg with over 10 hours autonomy, supporting 1 or 2 cartridges simultaneously

magia-diagnostics.com
+4 more records
Core offering1 text field

MagIA Diagnostics designs, develops, and manufactures a portable point-of-care immunodiagnostic platform based on superparamagnetic nanoparticles and structured micro-magnets. The MforScreen reader paired with proprietary MagIA Test cartridges performs multiplexed screening for HIV, Hepatitis B, Hepatitis C, and Syphilis from a single 50 µl blood sample in 12-15 minutes. The company also offers MforLab, a 96-well laboratory format for bio-production monitoring and mini-bioreactor control.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 6,700 samples tested for clinical validation
+3 more records
Product overview1 text field

MagIA Diagnostics offers a unified platform approach centered on two product lines: MforScreen (point-of-care) and MforLab (laboratory). The core MforScreen system is a portable immunodiagnostic reader paired with proprietary MagIA Test Kits (H3S) that perform multiplexed rapid screening for HIV, Hepatitis B, Hepatitis C, and Syphilis from a single blood sample. The MforLab variant adapts the same technology for bioproduction monitoring in 96-well format. The company is expanding through two strategic projects: MAGFA (focused on Sub-Saharan Africa screening) and MAGESTICS (expanding to bacterial STIs).

Product and service3 records
1MforScreen Point-of-Care Reader
CategoryIn Vitro Diagnostics Hardware
Description

Portable point-of-care diagnostic reader device weighing under 3.5 kg with over 10 hours of battery autonomy. Supports 1 or 2 cartridges simultaneously and records test results for traceability. Used by hospitals, clinical labs, and mobile screening teams for decentralized infectious disease testing.

2MagIA Test Kit (H3S Multiplex Cartridge)
CategoryIn Vitro Diagnostics Consumables
Description

Multiplexed rapid screening cartridge performing up to 5 analyses per cartridge (including 1 internal control) and up to 10 analyses per patient. Delivers results in 12-15 minutes using 50 µl of capillary blood, serum, plasma, or venous blood. Currently configured for combined HIV, Hepatitis B, Hepatitis C, and Syphilis detection.

3MforLab 96-Well Laboratory Format
CategoryLife Sciences Laboratory Equipment
Description

Laboratory-format version of the MagIA platform in 96-well format, designed for bio-production monitoring and real-time control of cell culture processes, including automated tracking of up to 24 mini bioreactors. Targeted at biopharmaceutical manufacturers, CMOs, and academic bioprocess laboratories.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

European MAGFA project coordination with Institut Pasteur for combined screening of HIV, hepatitis B/C, and syphilis in sub-Saharan Africa. Institut Pasteur serves as data analysis subcontractor for clinical studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NGO partnership for MAGFA project field coordination in the Democratic Republic of Congo. Dr. Olivier Kana leads national operations with site visits to Kinshasa for project planning.

3Lyonbiopôle Auvergne-Rhône-Alpes
Strategic tierCoreTypeGTM or Marketing Partner
Description

Regional healthcare cluster supporting MEDICA exhibition delegation and European project accompaniment for MagIA diagnostics.

magia-diagnostics.com
4TWB (Toulouse White Biotechnology)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MAGI@Line project for 96-well format installation and bioproduction monitoring. TWB serves as industrial integrator for demonstrating real-time cell culture monitoring.

magia-diagnostics.com
Strategic tierKeyTypeStrategic or Co-development Partner
Description

MAGESTICS project partnership to expand IST testing to include bacterial infections (Syphilis, Chlamydia, Gonorrhea) alongside viral infections.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration for MAGESTICS project and preliminary validation studies for hepatitis B diagnostic demonstrator.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Membership to leverage international promotion network for healthcare French companies.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Installation of 96-well format immunochemistry device for MAGI@Line project demonstration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner for Grand Défi Bioproduction project on biomedicament measurement technology.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Clinical investigation center collaboration for preliminary validation of hepatitis B IVD demonstrator with real patient analysis.

11Linksium
Strategic tierMinorTypeGTM or Marketing Partner
Description

Grenoble-based startup accelerator providing support and mentorship for deeptech challenges.

magia-diagnostics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global French IVD leader with extensive portfolio in clinical microbiology and immunoassays, including POC solutions. Directly comparable as a French-headquartered infectious disease diagnostics company with overlapping customer base (hospitals, reference labs) and competing POC platforms.

TypeDirect peer
Description

Pioneer of molecular POC diagnostics (GeneXpert), widely deployed for HIV, hepatitis, and STI screening in resource-limited settings including sub-Saharan Africa. Closely comparable as a multiplexed infectious disease POC platform competing for the same African public health and hospital tenders that MagIA targets.

3Abbott Diagnostics
TypeBroad incumbent
Description

Global leader in rapid diagnostic tests including Determine HIV/Hepatitis and Binax platforms used widely in African screening programs and European hospitals. Competes with MagIA across both its POC infectious disease core business and bioproduction QC opportunities.

TypeDirect peer
Description

Specialized POC diagnostics company with strong portfolio in rapid infectious disease testing (Sofia, Triage). Directly comparable as a multiplexed rapid immunoassay player targeting similar hospital and outreach screening customers as MagIA.

TypeDirect peer
Description

French-headquartered POC diagnostics company specializing in rapid infectious disease tests (COVID, HIV, hepatitis). Direct comparable as a France-based POC competitor with overlapping target markets in Europe and Africa.

6NG Biotech
TypeDirect peer
Description

French POC diagnostics company developing rapid multiplexed immunoassays for infectious disease and women's health. Direct comparable based on shared geography (France), technology category (multiplexed rapid immunoassays), and target applications (infectious disease POC).

TypeDirect peer
Description

US POC diagnostics company focused on infectious disease screening (HIV, HCV) with significant presence in public health programs. Comparable as a multiplexed rapid screening platform targeting similar at-risk and outreach screening use cases.

TypeDirect peer
Description

UK-based rapid diagnostics developer with strong focus on tropical and infectious disease POC tests, now part of Abbott. Comparable as a small-to-mid-stage POC innovator targeting global health and resource-limited settings.

TypeEmerging player
Description

Australian POC diagnostic company developing integrated rapid test devices for HIV and infectious diseases. Comparable as an emerging player in the rapid multiplexed POC space with similar early-stage commercial dynamics.

TypeEmerging player
Description

Canadian rapid diagnostics company with multiplexed POC tests for HIV, hepatitis, and syphilis. Comparable as a smaller, growth-stage POC infectious disease diagnostics peer with overlapping menu of tests.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MagIA Diagnostics

In Vitro Diagnosticsmagia-diagnostics.com

MagIA Diagnostics designs portable point-of-care immunoassay readers and multiplexed cartridges that screen for HIV, Hepatitis B/C, and Syphilis from a finger-prick blood sample in 12-15 minutes, serving hospitals, mobile screening units, public health programs in sub-Saharan Africa, and bioproduction customers.

What MagIA Diagnostics does

MagIA diagnostics SAS is a French in-vitro diagnostics (IVD) company founded in 2017 and headquartered in Échirolles (Grenoble). The company develops a portable point-of-care immunoassay platform built on proprietary superparamagnetic nanoparticle chemistry combined with structured micro-magnet architecture, originating from doctoral research at G2Elab and Institut Néel. Its flagship MforScreen reader weighs under 3.5 kg, runs for over 10 hours on battery, and accepts one or two single-use cartridges simultaneously. The paired MagIA Test Kit (H3S) performs multiplexed screening for HIV, Hepatitis B, Hepatitis C, and Syphilis in 12-15 minutes from 50 µl of capillary or venous blood. A laboratory-format variant, MforLab, extends the same chemistry to a 96-well plate format for bioproduction monitoring under the MAGI@Line project.

The business is currently pre-commercial: products are not yet CE marked, with submission targeted for 2025 following Phase 3 MAGICIENS clinical validation on approximately 6,700 samples. Revenue mechanics are anchored on future hardware (reader) sales paired with consumable cartridge revenue, complemented by European grant funding and collaborative research project income (MAGFA, MAGESTICS, Grand Défi Bioproduction). The go-to-market is a B2B enterprise field-sales motion targeting French and European hospitals, mobile screening units, sub-Saharan African public health programs (via Institut Pasteur and African NGO partners), and biopharmaceutical manufacturers for bioprocess analytics. Go-to-market is reinforced by presence at MEDICA, SFLS, EuroTestWeek, and the Lyonbiopôle/Novéka! cluster. The company has 23 employees, ISO 13485:2016 certification (September 2023), and cumulative funding of approximately €8.2 million across grants, seed, crowdfunding, and a 2024 IVD strategic round, with an additional €5 million earmarked via the European MAGFA project.

MagIA Diagnostics firmographics

Firmographics
Name
MagIA Diagnostics
Legal name
MagIA diagnostics SAS
Website
https://magia-diagnostics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
MagIA Diagnostics designs portable point-of-care immunoassay readers and multiplexed cartridges that screen for HIV, Hepatitis B/C, and Syphilis from a finger-prick blood sample in 12-15 minutes, serving hospitals, mobile screening units, public health programs in sub-Saharan Africa, and bioproduction customers.
Ownership category
akta.pro rank

MagIA Diagnostics industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Point-of-care diagnostics
  • Infectious disease screening
  • Multiplex immunoassay
  • Bioproduction monitoring
  • Rapid diagnostic tests

Where MagIA Diagnostics is headquartered

Location

Headquarters

HQ city
Grenoble
HQ country
France
HQ region
Europe

Offices1 record

Markets served

MagIA Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D

Revenue model

  1. Point-of-Care Diagnostic Kits and Readers: Sale of portable diagnostic devices (readers) and associated test cartridges for infectious disease screening. Revenue generated from hardware sales combined with consumable test kits.
  2. Laboratory Diagnostic Solutions: MforLAB platform for bioproduction monitoring and laboratory-scale analysis, including 96-well format devices and monitoring services.
  3. European Research Project Funding: MAGFA project with €5 million European funding; MAGESTICS project partnership with Infynity Biomarkers SAS and CHU Grenoble Alpes; Grand Défi Bioproduction funding for technology adaptation.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

MagIA Diagnostics product offering

Product offering

Core offering

MagIA Diagnostics designs, develops, and manufactures a portable point-of-care immunodiagnostic platform based on superparamagnetic nanoparticles and structured micro-magnets. The MforScreen reader paired with proprietary MagIA Test cartridges performs multiplexed screening for HIV, Hepatitis B, Hepatitis C, and Syphilis from a single 50 µl blood sample in 12-15 minutes. The company also offers MforLab, a 96-well laboratory format for bio-production monitoring and mini-bioreactor control.

Product overview

MagIA Diagnostics offers a unified platform approach centered on two product lines: MforScreen (point-of-care) and MforLab (laboratory). The core MforScreen system is a portable immunodiagnostic reader paired with proprietary MagIA Test Kits (H3S) that perform multiplexed rapid screening for HIV, Hepatitis B, Hepatitis C, and Syphilis from a single blood sample. The MforLab variant adapts the same technology for bioproduction monitoring in 96-well format. The company is expanding through two strategic projects: MAGFA (focused on Sub-Saharan Africa screening) and MAGESTICS (expanding to bacterial STIs).

Differentiator

Problem solved

Functional benefit

Brands

  • MforScreen: Point-of-Care portable diagnostic reader system weighing less than 3.5 kg with over 10 hours autonomy, supporting 1 or 2 cartridges simultaneously
  • MagIA test
  • MAGICS H3S
  • MAGFA
  • MAGESTICS

Products and services

  • MforScreen Point-of-Care Reader Portable point-of-care diagnostic reader device weighing under 3.5 kg with over 10 hours of battery autonomy. Supports 1 or 2 cartridges simultaneously and records test results for traceability. Used by hospitals, clinical labs, and mobile screening teams for decentralized infectious disease testing.
  • MagIA Test Kit (H3S Multiplex Cartridge) Multiplexed rapid screening cartridge performing up to 5 analyses per cartridge (including 1 internal control) and up to 10 analyses per patient. Delivers results in 12-15 minutes using 50 µl of capillary blood, serum, plasma, or venous blood. Currently configured for combined HIV, Hepatitis B, Hepatitis C, and Syphilis detection.
  • MforLab 96-Well Laboratory Format Laboratory-format version of the MagIA platform in 96-well format, designed for bio-production monitoring and real-time control of cell culture processes, including automated tracking of up to 24 mini bioreactors. Targeted at biopharmaceutical manufacturers, CMOs, and academic bioprocess laboratories.

Quantifiable outcome

  • 6,700 samples tested for clinical validation
  • +3 more outcomes

Companies that use MagIA Diagnostics

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

MagIA Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MagIA Diagnostics partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, key and minor.

  • Institut PasteurcoreStrategic or Co-development Partner · 1 October 2024European MAGFA project coordination with Institut Pasteur for combined screening of HIV, hepatitis B/C, and syphilis in sub-Saharan Africa. Institut Pasteur serves as data analysis subcontractor for clinical studies.
  • GARDIENS DE VIEScoreStrategic or Co-development PartnerNGO partnership for MAGFA project field coordination in the Democratic Republic of Congo. Dr. Olivier Kana leads national operations with site visits to Kinshasa for project planning.
  • Lyonbiopôle Auvergne-Rhône-AlpescoreGTM or Marketing PartnerRegional healthcare cluster supporting MEDICA exhibition delegation and European project accompaniment for MagIA diagnostics.
  • TWB (Toulouse White Biotechnology)coreStrategic or Co-development PartnerMAGI@Line project for 96-well format installation and bioproduction monitoring. TWB serves as industrial integrator for demonstrating real-time cell culture monitoring.
  • INFYNITY BIOMARKERS SASkeyStrategic or Co-development PartnerMAGESTICS project partnership to expand IST testing to include bacterial infections (Syphilis, Chlamydia, Gonorrhea) alongside viral infections.
  • CHU Grenoble AlpescoreStrategic or Co-development PartnerClinical collaboration for MAGESTICS project and preliminary validation studies for hepatitis B diagnostic demonstrator.
  • French Healthcare AssociationminorGTM or Marketing PartnerMembership to leverage international promotion network for healthcare French companies.
  • TIBHkeyStrategic or Co-development PartnerInstallation of 96-well format immunochemistry device for MAGI@Line project demonstration.
  • LRGP (Laboratoire Réactions et Génie des Procédés)minorStrategic or Co-development PartnerAcademic partner for Grand Défi Bioproduction project on biomedicament measurement technology.
  • CIC/CHUGAkeyStrategic or Co-development PartnerClinical investigation center collaboration for preliminary validation of hepatitis B IVD demonstrator with real patient analysis.
  • LinksiumminorGTM or Marketing PartnerGrenoble-based startup accelerator providing support and mentorship for deeptech challenges.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

MagIA Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • bioMérieux: Global French IVD leader with extensive portfolio in clinical microbiology and immunoassays, including POC solutions. Directly comparable as a French-headquartered infectious disease diagnostics company with overlapping customer base (hospitals, reference labs) and competing POC platforms.
  • Abbott Diagnostics: Global leader in rapid diagnostic tests including Determine HIV/Hepatitis and Binax platforms used widely in African screening programs and European hospitals. Competes with MagIA across both its POC infectious disease core business and bioproduction QC opportunities.

Direct peers

  • Cepheid (Danaher): Pioneer of molecular POC diagnostics (GeneXpert), widely deployed for HIV, hepatitis, and STI screening in resource-limited settings including sub-Saharan Africa. Closely comparable as a multiplexed infectious disease POC platform competing for the same African public health and hospital tenders that MagIA targets.
  • QuidelOrtho: Specialized POC diagnostics company with strong portfolio in rapid infectious disease testing (Sofia, Triage). Directly comparable as a multiplexed rapid immunoassay player targeting similar hospital and outreach screening customers as MagIA.
  • Biosynex: French-headquartered POC diagnostics company specializing in rapid infectious disease tests (COVID, HIV, hepatitis). Direct comparable as a France-based POC competitor with overlapping target markets in Europe and Africa.
  • NG Biotech: French POC diagnostics company developing rapid multiplexed immunoassays for infectious disease and women's health. Direct comparable based on shared geography (France), technology category (multiplexed rapid immunoassays), and target applications (infectious disease POC).
  • OraSure Technologies: US POC diagnostics company focused on infectious disease screening (HIV, HCV) with significant presence in public health programs. Comparable as a multiplexed rapid screening platform targeting similar at-risk and outreach screening use cases.
  • Mologic (Abbott Rapid Diagnostics): UK-based rapid diagnostics developer with strong focus on tropical and infectious disease POC tests, now part of Abbott. Comparable as a small-to-mid-stage POC innovator targeting global health and resource-limited settings.

Emerging players

  • Atomo Diagnostics: Australian POC diagnostic company developing integrated rapid test devices for HIV and infectious diseases. Comparable as an emerging player in the rapid multiplexed POC space with similar early-stage commercial dynamics.
  • MedMira: Canadian rapid diagnostics company with multiplexed POC tests for HIV, hepatitis, and syphilis. Comparable as a smaller, growth-stage POC infectious disease diagnostics peer with overlapping menu of tests.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

MagIA Diagnostics social profiles

Digital presence

MagIA Diagnostics compliance and trust

Trust signal

Compliance2 records

MagIA Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MagIA Diagnostics leadership team

Management profile

Number of profiles

Profiles8 records

MagIA Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MagIA Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MagIA Diagnostics

What does MagIA Diagnostics do?

MagIA Diagnostics designs, develops, and manufactures a portable point-of-care immunodiagnostic platform based on superparamagnetic nanoparticles and structured micro-magnets. The MforScreen reader paired with proprietary MagIA Test cartridges performs multiplexed screening for HIV, Hepatitis B, Hepatitis C, and Syphilis from a single 50 µl blood sample in 12-15 minutes. The company also offers MforLab, a 96-well laboratory format for bio-production monitoring and mini-bioreactor control.

Is MagIA Diagnostics a public or private company?

MagIA Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was MagIA Diagnostics founded?

MagIA Diagnostics was founded in 2017. It employs 11 to 50 people.

Where is MagIA Diagnostics based?

MagIA Diagnostics is headquartered in Grenoble, France, in the Europe region.

How does MagIA Diagnostics make money?

Three revenue lines are on record. Point-of-Care Diagnostic Kits and Readers are the primary driver. The others are laboratory Diagnostic Solutions and european Research Project Funding.

Who are MagIA Diagnostics's main competitors?

Broad incumbents on record are bioMérieux and Abbott Diagnostics. Direct peers are Cepheid (Danaher), QuidelOrtho, Biosynex, NG Biotech, OraSure Technologies and Mologic (Abbott Rapid Diagnostics). Emerging players are Atomo Diagnostics and MedMira.

Does MagIA Diagnostics have an API?

No public API is recorded for MagIA Diagnostics.

What industry is MagIA Diagnostics in?

MagIA Diagnostics's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales